Zibotentan/Dapagliflozin

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameZibotentan/Dapagliflozin
Drug Alias NameZibotentan达格列净
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type A antagonistsSodium/glucose cotransporter 2 inhibitors
TargetsEndothelin receptor type ASodium/glucose cotransporter 2
Therapy Area/IndicationsAlbuminuriaRenal Insufficiency, ChronicKidney Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[31] 
CombinationsYes ZibotentanDapagliflozin Propanediol Monohydrate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca AbAstraZeneca global R & D (China) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsAlbuminuriaRenal Insufficiency, ChronicKidney Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A